Test Price
2,800 AED✅ Home Collection Available
NDUFA1 Gene Mitochondrial Complex I Deficiency NGS Test in UAE
2,800 AED | 2026 DHA Guidelines
تحليل طفرة جين NDUFA1 ونقص المركب الأول في الميتوكوندريا في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
خلاصة تنفيذية
- ✓ دقة تشخيصية بنسبة 99.9% عبر التحليل الجيني المتقدم (NGS) تحت إجراءات آيزو 9001:2015.
- ✓ خدمة سحب دم منزلي على أعلى مستوى (كبار الشخصيات) بواسطة ممرضين متنقلين معتمدين مع سلسلة تبريد متوافقة مع المواصفات العالمية.
- ✓ استشارة طبية هاتفية بعد الفحص من قبل أطباء متخصصين لتفسير النتائج وربطها بالحالة السريرية.
- ✓ التحقق المباشر من تغطية التأمين عبر واتساب على الرقم +971 54 548 8731.
Overview
الاضطراب الميتوكوندري: The NDUFA1 gene encodes a crucial core subunit of the mitochondrial respiratory chain complex I; pathogenic variants cause mitochondrial complex I deficiency, a heterogeneous group of neurological disorders ranging from Leigh syndrome to MELAS-like phenotype. This NGS test sequences the entire coding region with near-100% sensitivity, enabling definitive diagnosis and family carrier screening in the UAE.
The test is performed on DNA extracted from blood or buccal swab/FTA card, requiring 3-4 weeks for full interpretation including in-silico protein modelling and variant classification per ACMG guidelines.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Full-gene NGS with copy number variant detection | Single-exon sequencing, no CNV detection |
| Analytical Sensitivity | >99.9% for substitutions & indels | ~95% per amplified fragment |
| Turnaround Time | 3-4 weeks | 6-8 weeks |
| Inheritance & Risk | Comprehensive pedigree integration | Limited to index case |
| UAE Regulatory Status | DHA/MOHAP licensed, ISO 9001:2015 | Often foreign labs, no local oversight |
Physician Insight & Safety Protocol
Note from Dr. PRABHAKAR REDDY (DHA: 61713011): “A positive NDUFA1 variant must always be interpreted in the context of the patient’s clinical picture and biochemical findings – not all sequence changes are disease-causing. Early diagnosis can open doors to supportive treatments and genetic counselling for at-risk family members, but the result is a piece of a larger puzzle, not the final word.”
Medication & Supplement Safety:
Do not discontinue prescribed medication without consulting your treating physician. No special drug restrictions for the test itself, but inform the phlebotomist of any anticoagulants (blood thinners) prior to collection.
Urgent Safety Notices – Exclusion Criteria & Red Flags
- Absolute exclusion: Active febrile illness or untreated infection requiring emergency care – postpone home collection and seek hospital evaluation.
- Red flag symptoms warranting immediate ER visit: Acute encephalopathy, new-onset seizures, sudden loss of motor skills, or unexplained metabolic acidosis.
- Minors: In accordance with UAE Federal Decree-Law No. 41 of 2024 (Art. 87) and CDS Law 2026, genetic testing on children requires documented consent from a legal guardian and a paediatric neurologist’s referral – home collection only with guardian present.
- Data Privacy: Your genetic data is protected under UAE PDPL and processed only on encrypted servers within the DHA-regulated facility (License: 9834453).
Patient FAQ & Clinical Guidance
1. What does a positive NDUFA1 test mean for my child’s neurological symptoms?
Direct answer: A positive result confirms a pathogenic variant in the NDUFA1 gene responsible for mitochondrial complex I deficiency, which directly explains the underlying cause of progressive neurological deterioration like hypotonia, developmental regression, or seizures. However, the specific prognosis depends on the exact mutation and biochemical severity, so results must be reviewed by a paediatric neurologist and metabolic specialist for individualised treatment planning.
النسخة العربية: النتيجة الإيجابية تؤكد وجود طفرة ممرضة في جين NDUFA1 مسؤولة عن نقص المركب الأول في الميتوكوندريا، مما يفسر السبب الكامن وراء الأعراض العصبية مثل ضعف العضلات، تراجع النمو، أو النوبات.
2. How reliable is this NGS test compared to older methods for mitochondrial disorders?
Direct answer: With >99.9% analytic sensitivity for single‑nucleotide variants and the ability to detect large deletions, this NGS assay is the most comprehensive method for mitochondrial gene testing, surpassing traditional Sanger sequencing which misses structural rearrangements and requires multiple separate reactions. The test follows ACMG variant interpretation guidelines and is performed in an ISO 9001:2015 certified facility, ensuring diagnostic-grade reliability accepted by all DHA and MOHAP hospitals.
3. Can I use my FTA card sample collected at home without a phlebotomist?
Direct answer: Yes, a self‑collected buccal swab or one‑drop blood on a DNA‑stabilizing FTA card is a fully accepted sample type for this, provided it is done following our instructional video and returned via prepaid courier; the extraction protocol yields high‑quality DNA with no loss of analytic sensitivity. However, for infants or patients with complex neurological conditions, we strongly recommend VIP home phlebotomy to ensure adequate sample volume and chain‑of‑custody compliance.
ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | UAE Federal Decree-Law No. 41 of 2024 & CDS Law 2026 Compliant | Data Protected under UAE PDPL
Support: WhatsApp +971 54 548 8731 | DHA Facility License: 9834453 | Medical Reviewer: Dr. Prabhakar Reddy, DHA 61713011
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians